Stock Rating Report for VNDA
|
|
Stock Information
| Ticker |
VNDA |
| Company Name |
Vanda Pharmaceuticals, Inc |
| Current Price |
$5.33 |
| Previous Close |
$5.33 |
| Industry |
Biotechnology |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for VNDA. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Vanda Pharmaceuticals, Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is also developing Tasimelteon, an orphan medicinal product for the treatment of sleep and mood disorders, including non-24 hour sleep/wake disorder in blind individuals without light perception. It also intends to initiate a Phase IIb/III clinical trial of tasimelteon in patients with major depressive disorder- and conduct additional clinical trials to support the use of tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.
|
Latest News
| Wed, 01 Feb 2012 01:40:45 GMT | 6 Highly Liquid Biotech Stocks With Positive Correlation To Volatility | | Thu, 26 Jan 2012 12:01:55 GMT | VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits | | Thu, 26 Jan 2012 12:00:00 GMT | Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder | | Sat, 21 Jan 2012 06:51:07 GMT | A Quant's View on the Resignations of TIAA-CREF's President, and the Co-Founder of Vanda Pharmaceuticals | | Fri, 20 Jan 2012 22:02:58 GMT | VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers | | Fri, 20 Jan 2012 00:24:32 GMT | A Quant Looks at a Network Connection -- TIAA CREF and Vanda Pharmaceuticals | | Thu, 19 Jan 2012 00:00:00 GMT | Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012 | | Wed, 18 Jan 2012 16:21:31 GMT | 8 Healthcare Stocks For Your 2012 Watchlists (Part 2) | | Fri, 13 Jan 2012 17:26:32 GMT | Smart Money, TIAA-CREF, Fidelity, and Vanda Pharmaceuticals | | Fri, 30 Dec 2011 12:01:14 GMT | VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement | | Tue, 27 Dec 2011 22:02:14 GMT | VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events | | Tue, 13 Dec 2011 12:08:21 GMT | Vanda signs exclusive license agreement with Megapharm for Fanapt in Israel | | Tue, 13 Dec 2011 12:00:00 GMT | Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt? in Israel | | Tue, 13 Dec 2011 11:06:28 GMT | Vanda Pharmaceuticals: Absurdly Undervalued And Prime Buyout Target | | Mon, 12 Dec 2011 23:41:40 GMT | Nasdaq stocks posting largest volume increases | | Mon, 12 Dec 2011 23:41:40 GMT | Nasdaq stocks posting largest volume increases | | Fri, 09 Dec 2011 22:06:33 GMT | VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers | | Sun, 20 Nov 2011 09:10:22 GMT | Biotech Focused Hedge Fund RA Capital's Top Q3 Picks | | Fri, 11 Nov 2011 18:04:45 GMT | VANDA PHARMACEUTICALS INC. Financials | | Mon, 07 Nov 2011 14:29:53 GMT | New Star Analyst Rankings for Vanda Pharmaceuticals Inc. | News provided by Yahoo! Finance |
|
|
|
|
